Page URL:

Event Review: Personal Genetics - An Intersection Between Science, Society, and Policy

11 March 2013
Appeared in BioNews 696

Personal Genetics: An Intersection Between Science, Society, and Policy

Organised by the American Association for the Advancement of Science and Harvard University

Room 203, John B Hynes Veterans Memorial Convention Centre, 900 Boylston Street, Boston 02115, Massachusetts, USA

Saturday 16 February 2013

'Personal Genetics: An Intersection Between Science, Society, and Policy', organised by the American Association for the Advancement of Science and Harvard University, Saturday 16 February 2013

In the decade since the human genome was first sequenced, the cost of reading a human genome has dropped from around US $100,000,000 to around US $6,000 (1). In the year since the organisers began putting together the symposium, 'Personalised Genetics: An Intersection between science, society and policy', to discuss the broader implications of personal genetics, the target has shifted from the '$1000 genome' to the '$0 genome'.

This plummeting cost is making the benefits of genome sequencing more accessible. Already, exome sequencing - sequencing all the portions of a person's genome that encode proteins - has proved useful in the diagnosis of rare genetic disorders. But our readiness to deal with the social and policy implications is not moving quite so fast. As Mira Irons, chief of clinical programs in genetics at Boston Children's Hospital, described it: 'The train has left the station and we're all out there running after that train'.

The symposium was part of the annual meeting of the American Association for the Advancement of Science and was organised by a group of biomedical PhD students from Harvard University. They selected speakers from a wide variety of backgrounds to discuss how we can help our lagging social and regulatory frameworks catch up with that personal genetics train. The discussion was wide-ranging and thoughtful, though as is usual for this kind of event, many more questions were asked than answered.

For example, how can we ensure that people who have their genome sequenced are able to provide truly informed consent? Jonathan Gitlin, a policy analyst at the US National Human Genome Research Institute and a writer at Ars Technica, pointed out that doctors testing a patient for variants at a single gene might take 15-20 minutes to ensure that the patient understands the risks and benefits well enough to give informed consent. In contrast, the procedure for exome sequencing includes a crash course in genomics and takes 6-9 hours. This poses a considerable problem for large-scale adoption of clinical genomics.

How to bridge the huge knowledge gap between genomics experts and the public was another question addressed in the discussion. One answer was suggested by Ting Wu, professor of genetics at Harvard Medical School. Wu founded the Personal Genetics Education Project, which seeks to increase awareness about the ethical dimensions of personal genetics, primarily by developing discussion-based school lesson plans. Wu described these discussions as deeply engaging experiences for students.

Mira Irons suggested that genetics education also needs to be intensified for healthcare professionals. She recognised the clinical potential of genomics but cautioned that 'in our clinics every day we see one or two patients that have had a genetic test that has been misinterpreted'.

Other problems discussed included ethnic disparities in genomic research, the constraints of communicating scientific advances in the media, a shifting and uncertain regulatory framework, and the impossibility of guaranteeing privacy to people who have their genome sequenced.

Gitlin also touched on current difficulties in interpreting personal genomics data. An interesting demonstration of this was provided by Brian Naughton, the founding scientist at US direct-to-consumer genomics company 23andMe. Naughton's presentation included discussion of his own exome sequence. Although this was not the main point of his presentation, he could not make any particularly useful conclusions about his exome data in spite of his expertise and his access to the aggregate data of 200,000 customers of 23andMe.

The speaker with the broadest approach to the issues was Sheila Jasanoff, professor of science and technology studies at Harvard Kennedy School. Using an extended political metaphor involving the television drama Downton Abbey, Jasanoff described an idealised genomics revolution.

This revolution is the transition from an era of symptomatic patients/subjects in clinical settings to a post-genomics era of asymptomatic customers/partners in commercial settings. The goal of this revolution is to see the authority-dominated past give way to a future that empowers citizens with information and personalised therapy. However, Jasanoff warned of the many problems with this dream, such as the potential for abuses of power. She suggested that we consider a new 'bill of rights' for 'citizens caught up in a revolution that offers distant horizons'.

Though I doubt we will ever marshal enough consensus for a biomedical bill of rights, the rapid approach of those distant horizons makes it important that we keep looking for answers to all those unresolved questions.

1) DNA Sequencing Costs
NHGRI Genome Sequencing Program |  11 February 2013
20 January 2014 - by Cait McDonagh 
A biotechnology company that produces genetically customised nutritional supplements has settled charges of deceptive advertising with the US Federal Trade Commission (FTC) over claims that its products could treat a number of ailments and diseases...
30 September 2013 - by Marco Narajos 
There is definitely great scope for expansion in genetics education through online courses, but these should be tailored towards the student's pace, however leisurely that might be...
20 May 2013 - by Chris Berry 
Earlier this month, over 180 delegates and speakers gathered in London for the final annual conference of the Economic and Social Research Council (ESRC) Genomics Network (EGN). After a decade of support from the ESRC, the EGN will officially draw to a close at the end of May...
13 May 2013 - by Simon Hazelwood-Smith 
I'd not been to a Cafe Scientifique event before and was a little unsure of what to expect. The Royal Brompton coffee shop setting did at first feel strange; I'm more used to discussions in lecture theatres where there is a clear distinction between audience and speaker...
25 March 2013 - by Nina Chohan 
The American College of Medical Genetics and Genomics has published a report recommending that patients who have their genomes sequenced should automatically be told of incidental genetic findings....
11 February 2013 - by Dr Barbara Prainsack and Dr Daniela Steinberger 
The Swiss Academy of Medical Sciences' position paper on the 'Potential and Limits of "Individualised Medicine"' illustrates a concerning instance of public fear mongering based on factual mistakes and misinformation...
5 November 2012 - by Professor Donna Dickenson 
The soaring promises made by personalised medicine advocates are probably loftier than in any other medical or scientific realm today. Francis Collins, former co-director of the Human Genome Project, wrote: 'We are on the leading edge of a true revolution in medicine, one that promises to transform the traditional "one size fits all" approach into a much more powerful strategy'...
8 August 2011 - by Dr Rebecca Hill 
'The age of personalised medicine: genes, privacy and discrimination?' was the last in BioCentre's 2010/2011 symposium series 'Revolution, Regulation and Responsibilities', and promised to 'appraise current developments and consider the current legal and regulatory position for their use before taking time to reflect and assess the future impact on society'...
25 October 2010 - by Professor Christopher Hood 
Direct-to-consumer personal genetic profiling services marketed as a way to predict people's future health risks may claim to be leading a new era of 'personalised healthcare', but the Nuffield Council on Bioethics believe these claims should be treated with caution...
18 October 2010 - by Dr Vivienne Raper 
Would you publish your genome? Last week, the 12-member Genomes Unzipped project published their direct-to-consumer genetic test results online. They say they're dispelling fears and encouraging discussion about what genetics means for society. But, in a Royal Institution debate on Thursday, Wellcome Trust Director Sir Mark Walport said openly disclosing their DNA would - like drunken Facebook party pictures - return to haunt them...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.